NIH's history keeper retires

To intramural scientists at the US National Institutes of Health whose endgame is being published, scrawled notations, E-mail exchanges and antiquated lab instruments are the flotsam and jetsam of research. But to Victoria A. Harden, founder of the Office of NIH History, these materials are gold. "The American people were putting billions of dollars into the NIH and they were getting a tremendous product for the money, and nobody knew about it," says the 62-year-old Ha

Written byKaren Pallarito
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

To intramural scientists at the US National Institutes of Health whose endgame is being published, scrawled notations, E-mail exchanges and antiquated lab instruments are the flotsam and jetsam of research. But to Victoria A. Harden, founder of the Office of NIH History, these materials are gold. "The American people were putting billions of dollars into the NIH and they were getting a tremendous product for the money, and nobody knew about it," says the 62-year-old Harden, who retired on January 31 after 20 years as the agency's chief historian.

The Marietta, Ga., native had two children and taught part-time before pursuing her PhD in American history, never imagining she would work for the federal government. But while studying at Emory University, Harden stumbled upon some papers by a Georgia chemist who lobbied in the late 1920s for the establishment of the National Institute (singular) of Health. It was a pivotal ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies